Less Ads, More Data, More Tools Register for FREE

IP Group invests in inventors' network

Wed, 06th Jun 2012 07:20
IP Group, the FTSE 250 intellectual property development firm, is to invest in a new platform which aims to increase the chances of turning scientific discoveries into viable products and businesses.The Marblar platform is an online network for inventors to interact directly with the scientific research community to come up with new ways to exploit scientific discoveries. IP Group says it has already conducted a pilot of the scheme using discoveries in DNA chemistry from the Southampton Nucleic Acid Research group. The intellectual property related to the DNA discoveries was placed on the Marblar network, then inventors competed to come up with the best uses for it. The firm says within three weeks one inventor had come up with an application which is already being assessed as a possible spin out company.IP Group's total investment could reach £371,000, which would leave it with a 33.1% interest in Marblar.Alan Aubrey, Chief Executive Officer (CEO) of IP Group, said: "What Marblar is offering is an innovative way of unearthing new applications for existing science that might otherwise be overlooked and complements our existing model. We see this as a great source of new ideas, and potentially new companies, that could ultimately benefit UK plc as a whole."Dan Perez, CEO of Marblar, added: "It's a shame that more than 90% of university disclosures sit on a shelf collecting dust because the path to market isn't obvious. Together with our 'Marblars', we're going to change that and, in the process, change the world."BS Ip Group

Shares in this article

Related News

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track
3 Jun 2026

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday.

IP Group cheers trial results for Enterprise drug candidate
12 May 2026

IP Group cheers trial results for Enterprise drug candidate

(Alliance News) - IP Group PLC on Monday noted positive test results for a cystic fibrosis treatment developed by one of its portfolio firms.

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint
7 May 2026

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint

IP Group PLC - London-based investor in "breakthrough" science and technology firms - Appoints Michael Queen as chair designate, and as a non-executi...

Corporate News Ip Group + 1 more share